profit from every $100 of sales.
$0$100
Cabaletta Bio
$1.28-3.76% today
-45.3% in 1 year
1-year low $1.281-year high $4.15
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Cabaletta Bio sold, what it kept, and what it did with the cash.
Sales went from $0 in 2022 to $0 in 2025, with -$168 million of profit last year.
SalesProfit
Cabaletta Bio vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Cabaletta Bio | No profit yet | ||
 Vertex Pharmaceuticals | 34.5× · Expensive | ||
 Regeneron Pharmaceuticals | 21.9× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads Cabaletta Bio's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 0 | 0 | 0 | |
| – | – | – | – | |
| -54 | -75 | -125 | -172 | |
| -53 | -66 | -113 | -164 | |
| -53 | -68 | -116 | -168 | |
| -1.81 | -1.65 | -2.34 | -2.10 | |
| – | – | – | – | |
| – | – | – | – | |
| – | – | – | – |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 117 | 254 | 185 | 165 |
| Cash | 82 | 193 | 164 | 83 |
| Total debt | 5 | 5 | 16 | 27 |
| Total liabilities | 12 | 17 | 33 | 53 |
| 105 | 236 | 152 | 112 | |
| 29 | 41 | 50 | 80 | |
| -39.0% | -22.2% | -54.2% | -94.2% | |
| -50.7% | -28.7% | -76.1% | -149.8% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -46 | -54 | -88 | -131 | |
| 2 | 1 | 2 | 1 | |
| -49 | -54 | -90 | -132 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 7 | 11 | 19 | 21 |
Valuation
- –
- –
- –
- 3.7×
- –
- –
- –
- -47.9%
- -60.8%
- 0.0%
Profitability
- 0.0%
- 0.0%
- 0.0%
- 0.0%
- -138.3%
- -61.0%
- -131.6%
- -118.4%
- -168.2%
- –
Growth
- –
- –
- −46.3%
- –
- +41.2%
Financial health
- 0.5×
- 0.26
- 17.9%
- -76.5×
- 2.95
- 2.95
- 0.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 21%of 871
Bottom 1%of 986
What analysts expect
- Average price target
- $16.33
- Range
- $3.00 – $32.00
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 14, 2026 | -0.39 | -0.41 | +4.9% |
| Mar 23, 2026 | -0.40 | -0.45 | +11.1% |
| Nov 10, 2025 | -0.44 | -0.49 | +10.2% |
| Aug 7, 2025 | -0.73 | -0.71 | −2.8% |
| May 15, 2025 | -0.71 | -0.67 | −6.0% |
| Mar 31, 2025 | -0.65 | -0.65 | +0.0% |
| Nov 14, 2024 | -0.62 | -0.59 | −5.1% |
| Aug 8, 2024 | -0.56 | -0.55 | −1.8% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
21No pass
Benjamin Graham
38No pass
Philip Fisher
32No pass
Peter Lynch
56No pass
Joel Greenblatt
0No pass
Charlie Munger
25No pass
Terry Smith
23No pass
Questions about Cabaletta Bio
Is Cabaletta Bio a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Cabaletta Bio AI analysis
What does Cabaletta Bio do?
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. It is in Biotechnology.
Does Cabaletta Bio pay a dividend?
No. Cabaletta Bio does not pay a dividend at the moment.
Is Cabaletta Bio stock halal?
Questionable. Cabaletta Bio sits in a grey zone: its cash and confirmed interest-bearing investments are 30% of its market value, between 30% and 33%. How we check
How has Cabaletta Bio stock done over the past year?
Down 45.3% over the past twelve months, to $1.28. It traded between $1.28 and $4.15 and is 69.2% below its high.
Who are Cabaletta Bio's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with Cabaletta Bio's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.